ATXSFinance•businesswire•
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment:Negative (5)
Summary
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria’s common stock on August 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were gran
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 4, 2025 by businesswire